Galina 2014 Int J Biochem Cell Biol: Difference between revisions
(Created page with "{{Publication |title=Galina A. (2014) Mitochondria: 3-Bromopyruvate vs. mitochondria? A small molecule that attacks tumors by targeting their bioenergetic diversity. Insect Bioch...") ย |
|
(No difference)
|
Revision as of 13:19, 5 June 2014
Galina A. (2014) Mitochondria: 3-Bromopyruvate vs. mitochondria? A small molecule that attacks tumors by targeting their bioenergetic diversity. Insect Biochem Mol Biol S1357-2725. |
Galina A (2014) Int J Biochem Cell Biol
Abstract: Enhanced glycolysis, the classic bioenergetic phenotype of cancer cells was described by Otto Warburg approximately 90 years ago. However, the Warburg hypothesis does not necessarily imply mitochondrial dysfunction. The alkyl-halogen, 3-bromopyruvate (3BP), would not be expected to have selective targets for cancer therapy due to its high potential reactivity toward many SH side groups. Contrary to predictions, 3BP interferes with glycolysis and oxidative phosphorylation in cancer cells without side effects in normal tissues. The mitochondrial hexokinase II has been claimed as the main target. This "Organelle in focus" article presents a historical view of the use of 3BP in biochemistry and its effects on ATP-producing pathways of cancer cells. I will discuss how the alkylated enzymes contribute to the cooperative collapse of mitochondria and apoptosis. Perspectives for targeting 3BP to bioenergetics enzymes for cancer treatment will be considered. โข Keywords: 3-Bromopyruvate, Glycolytic inhibitor, Mitochondrial respiration inhibitor, Alkylation, Tumor cell metabolism
โข O2k-Network Lab: BR Rio de Janeiro Galina A, BR Rio de Janeiro Institute Biomedical Chemistry
Labels: MiParea: Respiration
Pathology: Cancer
HRR: Oxygraph-2k
Review